Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

ASCO 2024

31 May - 4 Jun 2024

Published: 2 Jun 2024

Views: 123

Rating:

Save

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA

Prof Heinz-Josef Lenz speaks to ecancer at ASCO 2024 about the expanded efficacy analysis from CheckMate 8HW.

This study evaluates nivolumab plus ipilimumab versus chemotherapy as first-line treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer.

In the previous analysis, nivolumab plus ipilimumab demonstrated superior progression-free survival versus chemotherapy.

Prof Lenz reports that the clinical benefit with first line nivolumab plus ipilimumab versus chemotherapy was maintained after subsequent therapy, as shown by improved progression-free survival 2 in patients with centrally confirmed MSI-H/dMMR mCRC.

Related Videos

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms ( Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Lenvatinib plus pembrolizumab versus standard of care for previously treated...

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

More from ecancer